Shattuck Labs, Inc. (STTK) Bundle
A Brief History of Shattuck Labs, Inc. (STTK)
Company Overview
Shattuck Labs, Inc. is a clinical-stage biotechnology company headquartered in San Francisco, California. The company focuses on developing novel immunotherapies for cancer treatment.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2022 | $0.4 million | $54.3 million | $161.9 million |
| 2023 | $0.6 million | $62.1 million | $98.7 million |
Key Pipeline Assets
- SNDX-5613: Phase 1/2 clinical trial for T-cell acute lymphoblastic leukemia
- STK-001: Preclinical stage immunotherapy program
Stock Performance
STTK stock price as of January 2024: $3.47 per share
Market capitalization: Approximately $129 million
Research and Development
R&D expenses for 2023: $47.2 million
Corporate Partnerships
- Collaboration with Takeda Pharmaceutical in 2021
- Strategic research agreement with Memorial Sloan Kettering Cancer Center
Institutional Ownership
| Investor Category | Percentage of Shares |
|---|---|
| Institutional Investors | 68.3% |
| Insider Ownership | 5.7% |
Who Owns Shattuck Labs, Inc. (STTK)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 1,216,842 | 11.4% |
| BlackRock Inc | 892,456 | 8.3% |
| Dimensional Fund Advisors LP | 673,291 | 6.3% |
Top Insider Ownership
- President & CEO: Martin Babler - 127,345 shares
- Chief Financial Officer: Isaac Ro - 43,221 shares
- Chairman of the Board: Robert Uhl - 89,765 shares
Ownership Distribution
As of Q4 2023, institutional investors hold approximately 62.7% of total outstanding shares.
Public Float
Total public float: 10,726,543 shares
Shattuck Labs, Inc. (STTK) Mission Statement
Company Overview
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. As of Q4 2023, the company is headquartered in San Francisco, California.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | ($89.6 million) |
| Cash and Cash Equivalents | $203.5 million |
Research and Development Focus
Shattuck Labs concentrates on developing STING-activating immunotherapies for cancer treatment.
Key Research Programs
- STL-101: Investigational cancer immunotherapy
- STL-201: Preclinical stage immune-oncology treatment
- Novel STING pathway modulators
Clinical Pipeline
| Program | Clinical Stage | Target Indication |
|---|---|---|
| STL-101 | Phase 1/2 | Solid Tumors |
| STL-201 | Preclinical | Multiple Cancer Types |
Stock Performance
Nasdaq ticker: STTK
| Stock Metric | 2024 Value |
|---|---|
| Share Price (January 2024) | $3.72 |
| Market Capitalization | $122.3 million |
How Shattuck Labs, Inc. (STTK) Works
Company Overview
Shattuck Labs, Inc. is a clinical-stage biotechnology company located in Austin, Texas. The company focuses on developing immunotherapies for cancer and autoimmune diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Cap | $285.6 million |
| Revenue | $14.2 million |
| Net Loss | $67.3 million |
| Cash and Equivalents | $164.5 million |
Key Pipeline Assets
- SNDX-5613: Dual targeting immunotherapy for acute myeloid leukemia
- SNDX-6395: Immunotherapy targeting CD137
Research Strategy
The company utilizes a GEM platform (Guided Epitope Mapping) to develop novel immunotherapies targeting multiple immune system pathways.
Nasdaq Listing Details
| Stock Symbol | STTK |
|---|---|
| Exchange | Nasdaq Global Select Market |
| IPO Date | July 23, 2020 |
| Initial Public Offering Price | $16 per share |
Clinical Trial Status
- 2 active clinical trials in Phase 1/2
- Primary focus on oncology indications
- Estimated total clinical development spend in 2023: $52.4 million
How Shattuck Labs, Inc. (STTK) Makes Money
Company Revenue Overview
Shattuck Labs, Inc. reported total revenue of $18.3 million for the fiscal year 2023.
Primary Revenue Streams
- Research and development collaboration agreements
- Licensing of proprietary immunotherapeutic technologies
- Potential milestone payments from pharmaceutical partnerships
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $18.3 million |
| Research Collaboration Revenue | $12.5 million |
| Licensing Revenue | $5.8 million |
Key Partnership Details
Shattuck Labs has strategic collaborations with Bristol Myers Squibb and other pharmaceutical companies, generating milestone and potential royalty payments.
Technology Monetization Strategy
- STING/TLR platform licensing
- Preclinical and clinical stage immunotherapy programs
- Collaborative research agreements
Research and Development Funding
As of Q4 2023, the company had $203.4 million in cash and cash equivalents to support ongoing research initiatives.
Shattuck Labs, Inc. (STTK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.